How Bitterman was paid
$387,019 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Other | Total |
|---|---|---|---|---|
| Robert J. BittermanPresident and Chief Executive Officer | $342,615 | $43,245 | $1,159 | $387,019 |
| Robert M. InfarinatoVice President and Chief Financial Officer | $75,462 | $29,330 | $414 | $105,206 |
What changed and why
- $387K$387,019 was CEO total compensation in 2024, down from $437,892 in 2023.
- $43,245$43,245 of CEO compensation was restricted stock unit awards.
- Neither named executive received an annual incentive bonus payment in 2024.
- 1-year vesting replaced 3-year vesting for employees’ unvested restricted stock units.
- 40%40% was the CEO’s annual bonus opportunity under his employment agreement.
- $105K$105,206 was total compensation for CFO Robert M. Infarinato, appointed August 1, 2024.
Other Phio Pharmaceuticals proxy statements
- 2026 proxy statement
Robert J. Bitterman paid $1.2M (+200% on the year).
Filed Aug 14, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.